# Vincristine

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vincristine
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** VCR, Oncovin, Vincasar, Leurocristine, 22-Oxovincaleukoblastine, Catharanthus roseus alkaloid, Madagascar periwinkle alkaloid, Vinca alkaloid, Rosy periwinkle extract

## Overview

Vincristine is a vinca alkaloid derived from the periwinkle plant Catharanthus roseus that binds tubulin dimers to inhibit microtubule polymerization, arresting cell division at metaphase. It is a cornerstone chemotherapy agent used in treatment protocols for acute lymphoblastic leukemia, Hodgkin lymphoma, and several solid tumors.

## Health Benefits

• Essential medicine for treating leukemias, lymphomas, and testicular cancer (noted as essential medicine, specific trial data not provided)
• Anti-tumor activity through microtubule disruption in rapidly dividing cells (mechanism established)
• Targets cancer cells during mitosis by preventing spindle formation (mechanism established)
• Part of combination chemotherapy protocols for various cancers (clinical use noted)
• Derived from plant with centuries of traditional anti-tumor use (traditional evidence only)

## Mechanism of Action

Vincristine binds with high affinity to beta-tubulin subunits, preventing the polymerization of tubulin dimers into microtubules and causing depolymerization of existing spindle fibers, which halts mitosis at the metaphase-anaphase transition. This mechanism induces G2/M cell cycle arrest and triggers intrinsic apoptotic pathways via cytochrome c release and caspase-3 activation. Rapidly dividing cells such as cancer cells are disproportionately affected due to their heightened dependence on intact mitotic spindle assembly.

## Clinical Summary

Vincristine has been evaluated in thousands of clinical trials since the 1960s and is a WHO Essential Medicine incorporated into standard multi-agent regimens such as CHOP, MOPP, and the ALL Berlin-Frankfurt-Münster protocol. In pediatric ALL trials, vincristine-containing induction regimens achieve complete remission rates exceeding 95% in children, establishing it as one of the most effective antineoplastic agents ever developed. Randomized controlled trials in adult diffuse large B-cell lymphoma using CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) demonstrate 5-year overall survival rates of approximately 58–65%. Evidence quality is high given decades of controlled trial data, though direct head-to-head comparisons isolating vincristine's individual contribution are limited by its universal inclusion in combination regimens.

## Nutritional Profile

Vincristine is a purified alkaloid compound (molecular formula C46H56N4O10, molecular weight 824.96 g/mol), not a food or nutritional substance. It contains no macronutrients (0g protein, 0g carbohydrates, 0g fat), no dietary fiber, no vitamins, and no dietary minerals in any nutritional sense. As a pharmaceutical compound, it is administered intravenously at therapeutic doses typically ranging from 1.0–1.4 mg/m² body surface area. The active moiety is the vinca alkaloid structure derived originally from Catharanthus roseus (periwinkle plant). Bioactive compound concentration in pharmaceutical formulations: vincristine sulfate 1 mg/mL in sterile solution. Bioavailability: 100% by definition via IV administration; oral bioavailability is negligible due to poor gastrointestinal absorption and first-pass [metabolism](/ingredients/condition/weight-management). The compound binds tubulin at a 1:1 molar ratio (Kd approximately 1–2 µM). No caloric value. No nutritional profile is applicable; characterization is purely pharmacological and toxicological rather than nutritional.

## Dosage & Preparation

No clinically studied dosage ranges for different forms (extract, powder, standardized) are available in the research results. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Vincristine's primary dose-limiting toxicity is peripheral neuropathy, manifesting as paresthesias, motor weakness, and autonomic dysfunction, which occurs in a significant proportion of patients and may be irreversible at cumulative doses above 15–20 mg. Severe vinca alkaloid-induced neurotoxicity is more pronounced in patients with pre-existing neuropathy, hepatic impairment (which reduces vincristine clearance via CYP3A4), or concurrent use of azole antifungals, macrolide antibiotics, or HIV protease inhibitors that inhibit CYP3A4 [metabolism](/ingredients/condition/weight-management). Vincristine is classified FDA Pregnancy Category D and is contraindicated in pregnancy; intrathecal administration is uniformly fatal and represents a critical medication error risk requiring specific handling protocols. Myelosuppression is less prominent than with other vinca alkaloids but constipation, ileus, and SIADH-related hyponatremia are clinically significant adverse effects requiring monitoring.

## Scientific Research

The research dossier lacks specific details on key human clinical trials, RCTs, or meta-analyses for vincristine, including study designs, sample sizes, or outcomes. While noted as an essential medicine for various cancers, no trial data or PubMed PMIDs are provided in the available research.

## Historical & Cultural Context

Catharanthus roseus (rosy periwinkle) was used for centuries in folk remedies of Madagascar, Southern Africa, and the ancient Ayurveda system as an anti-tumor and anti-mutagenic agent. Studies in the 1950s identified over 120 alkaloids in the plant, leading to the isolation of vincristine and vinblastine.

## Synergistic Combinations

Vinblastine, other vinca alkaloids, vindoline, catharanthine

## Frequently Asked Questions

### What is vincristine used to treat?

Vincristine is used to treat acute lymphoblastic leukemia (ALL), Hodgkin and non-Hodgkin lymphoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, and small cell lung cancer. It is almost always administered as part of combination chemotherapy regimens such as CHOP or BFM-based ALL protocols rather than as a single agent.

### How does vincristine kill cancer cells?

Vincristine binds to beta-tubulin and prevents the assembly of microtubules, which are essential structural components of the mitotic spindle required to separate chromosomes during cell division. This arrests dividing cells at the metaphase-anaphase boundary, ultimately triggering apoptosis via caspase activation. Because cancer cells divide more rapidly than most normal cells, they are selectively vulnerable to this mechanism.

### What are the most common side effects of vincristine?

The most clinically significant side effect is peripheral neuropathy, including numbness, tingling, loss of deep tendon reflexes, foot drop, and autonomic dysfunction such as constipation and ileus, which can be dose-limiting and sometimes irreversible. Other common effects include alopecia, jaw pain, and syndrome of inappropriate antidiuretic hormone secretion (SIADH) causing hyponatremia. Unlike many chemotherapy agents, vincristine causes relatively mild bone marrow suppression.

### What drugs interact with vincristine?

Vincristine is metabolized primarily by CYP3A4, so potent inhibitors of this enzyme—including azole antifungals like itraconazole, macrolide antibiotics like erythromycin, and HIV protease inhibitors like ritonavir—significantly increase vincristine plasma levels and neuropathy risk. Concurrent use with L-asparaginase can reduce hepatic vincristine clearance and should be sequenced carefully. Drugs that independently cause neuropathy, such as platinum compounds or taxanes, compound neurotoxic risk when co-administered.

### What plant does vincristine come from?

Vincristine is derived from Catharanthus roseus, commonly known as the Madagascar periwinkle or rosy periwinkle, a flowering plant historically used in traditional medicine in multiple cultures. It is one of two clinically important vinca alkaloids isolated from this plant, the other being vinblastine; both share a mechanism of tubulin binding but differ in their toxicity profiles and clinical indications. The discovery of these alkaloids in the 1950s–1960s by researchers including Gordon Svoboda transformed pediatric leukemia from a uniformly fatal disease to one with high cure rates.

### Is vincristine safe to use during pregnancy or while breastfeeding?

Vincristine is contraindicated during pregnancy as it can cause severe fetal harm and birth defects due to its mechanism of disrupting cell division. Women of childbearing age should use effective contraception during treatment, and breastfeeding is not recommended while receiving vincristine therapy due to the risk of exposing infants to the drug through breast milk.

### What clinical evidence supports the effectiveness of vincristine for cancer treatment?

Vincristine has decades of clinical trial data demonstrating its efficacy as part of combination chemotherapy protocols for acute lymphoblastic leukemia, Hodgkin's lymphoma, and testicular cancers, with significantly improved remission and survival rates compared to historical controls. The World Health Organization includes vincristine on its Essential Medicines List based on substantial evidence from thousands of patients across multiple cancer types.

### How is vincristine administered and what is the typical dosing schedule?

Vincristine is administered intravenously, typically as a weekly injection in most chemotherapy protocols, with doses carefully calculated based on patient body surface area to minimize toxicity. Treatment schedules vary depending on the specific cancer type and combination regimen being used, ranging from single-agent therapy to multi-drug protocols lasting several months or longer.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*